Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2023; 14(7): 1112-1125
Published online Jul 15, 2023. doi: 10.4239/wjd.v14.i7.1112
Glucose metabolism profile recorded by flash glucose monitoring system in patients with hypopituitarism during prednisone replacement
Min-Min Han, Jia-Xin Zhang, Zi-Ang Liu, Lin-Xin Xu, Tao Bai, Chen-Yu Xiang, Jin Zhang, Dong-Qing Lv, Yan-Fang Liu, Yan-Hong Wei, Bao-Feng Wu, Yi Zhang, Yun-Feng Liu
Min-Min Han, Jia-Xin Zhang, Lin-Xin Xu, Tao Bai, Chen-Yu Xiang, Jin Zhang, Dong-Qing Lv, Yan-Fang Liu, Yan-Hong Wei, Bao-Feng Wu, Yun-Feng Liu, Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China
Min-Min Han, Jia-Xin Zhang, Bao-Feng Wu, Yun-Feng Liu, The First Clinical Medical College of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China
Zi-Ang Liu, Department of General Medicine, The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030000, Shanxi Province, China
Yi Zhang, Department of Pharmacology, Shanxi Medical University, Taiyuan 030000, Shanxi Province, China
Author contributions: Liu YF was the guarantor and designed the study; Liu ZA, Xu LX, Bai T, Xiang CY, Zhang J, Lv DQ, Liu YF, Wei YH, and Wu BF participated in the acquisition of the data; Han MM, Zhang JX, and Liu ZA analyzed and interpreted the data; Han MM and Zhang JX drafted the initial manuscript; Liu YF, Zhang Y, and Han MM revised the article critically for important intellectual content.
Supported by National Natural Science Foundation of China, No. 81770776, No. 81973378, and No. 82073909; The Shanxi Provincial Central Leading Local Science and Technology Development Fund Project, No. YDZJSX2022A059; and Postgraduate Education Innovation Project of Shanxi Province, No. 2022Y354.
Institutional review board statement: The study was reviewed and approved by Ethic Committee in First Hospital of Shanxi Medical University (Taiyuan), No. [2019]Y20.
Informed consent statement: Written informed consent was obtained from all the subjects after explanation of study design and purpose.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: The analyzed data presented in the study are included in the article, further inquiries can be directed to the corresponding authors.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yun-Feng Liu, MD, PhD, Chief Physician, Professor, Department of Endocrinology, First Hospital of Shanxi Medical University, No. 85 Jiefang Nan Road, Taiyuan 030000, Shanxi Province, China. nectarliu@163.com
Received: March 13, 2023
Peer-review started: March 13, 2023
First decision: May 12, 2023
Revised: May 17, 2023
Accepted: May 30, 2023
Article in press: May 30, 2023
Published online: July 15, 2023
Processing time: 122 Days and 6.2 Hours
Core Tip

Core Tip: Glucocorticoids (GCs) replacement regimens for patients with hypopituitarism are hard to mimic physiological cortisol rhythms and carry risks of over-treatment, which can have adverse effects on glucose metabolism. We assessed the glucose metabolism profile of patients with hypopituitarism receiving prednisone (Pred) replacement, using a flash glucose monitoring system, to clarify impacts of different GCs preparations and prescriptions on glycometabolism, along with the resultant risks of consequent cardiovascular events. The study showed that Pred replacement disturbed glycometabolic homeostasis in patients with hypopituitarism. A dose of > 5 mg/d Pred caused more adverse effects on glycometabolism than ≤ 5 mg/d, contributing to the higher risks of cardiovascular events.